ANDHealth has been recognised internationally as one of only 11 nominees worldwide in the Best Incubators, Accelerators and Equity category of the 2026 Prix Galien USA Awards, announced in New York City on 29 October 2026.

The Prix Galien USA Awards, widely regarded as the life sciences equivalent of the Nobel Prize, recognise excellence in the biopharmaceutical, medical technology and digital health industries.

This year, ANDHealth became the first Australian commercialisation organisation ever nominated for a Prix Galien USA Award, recognised for its flagship ANDHealth+ incubator program. The 2026 category winner was PureTech Health.

“Congratulations to PureTech Health and to all the nominees. To be considered alongside organisations of this calibre is a milestone for Australian health innovation,” Ms Le Grice said.

ANDHealth+ now in its eighth year, is Australia’s only program exclusively focused on accelerating and incubating next generation digital and connected health technologies. Funded by the Australian Government through the Medical Research Future Fund (MRFF), the program draws on a network of partner organisations and industry leaders from around the globe, alongside non-dilutive funding from the MRFF, to support companies to commercialise their technology faster and more effectively.  

As a non-profit and non-equity taking program, its primary focus is on providing proven commercialisation and go-to-market support which changes the growth trajectory of Australia’s most innovative companies.  

ANDHealth Founder and CEO Bronwyn Le Grice said the nomination placed ANDHealth’s model for supporting health technology commercialisation alongside the best in the world.

“Australia has leaned into the idea that we are great at research and poor at commercialisation for decades. This recognition shows we can build programs and models to support innovators in Australia, which are truly competitive on a global scale, when we focus on building specifically for commercialisation rather than treating it as an add-on for research,” Ms Le Grice said.

“ANDHealth+ demonstrates what a program designed specifically for commercialisation can do. By harnessing the capabilities of industry representatives from across multiple sectors, leading academic institutions and a vibrant international network, we have built an innovation and commercialisation multiplier for Australia, supporting hundreds of companies every year, at every stage from idea to exit.”

The Australian recognition by the Prix Galien USA Awards also extended to two companies supported through ANDHealth Medical Research Future Fund (MRFF)-backed programs: Perth-based OncoRes Medical, nominated for Best Startup for its cancer-surgery imaging technology, and Gheorg, nominated for Best Digital Health Solution for its digital mental health tool for children. ANDHealth, OncoRes Medical and Gheorg are all founded and led by women. The Best Digital Health Solution category was won by AEYE Health and the Best Startup was won by Strand Therapeutics.

“I congratulate OncoRes Medical and Gheorg on their nominations. ANDHealth+ is only as successful as the companies it supports, so having two of our portfolio companies also nominated for the Prix Galien USA Awards is incredibly exciting and further demonstration that Australia is developing and commercialising technology that has relevance to patients around the world.”

The 28 ANDHealth+ alumni companies have collectively raised more than $223 million in follow-on funding, generated more than $101 million in new revenue, created more than 550 jobs, undertaken 52 international market launches, achieved 36 regulatory clearances, and reached more than 5.2 million patients, with more than 80% now generating revenue. Since 2021, every ANDHealth+ alumni company has gone on to secure follow-on funding.

ANDHealth was also awarded silver in the Medical category of the 2026 Australian Financial Review (AFR) BOSS Most Innovative Companies Awards in Sydney last week, earning national and international recognition for the ANDHealth+ program in the same year.

Ms Le Grice said the recognition came at an opportune time as innovation funding and capital continues to be squeezed in the current economic climate.

“Commercialising new technologies which change patient lives is incredibly complex and costly and carries enormous amounts of risk for both founders and investors. Continuing to invest in these industries, in specialised commercialisation capability and in creating an environment that attracts high-quality private capital into innovative companies, is critical for Australia’s future prosperity and the health of our nation.”

“This recognition shows we can compete with the best in the world, and we encourage Australia to continue to invest in its innovators as they take their technologies to the globe.”

Looking forward, Ms Le Grice said she was hopeful the recognition would trigger a new phase of growth for ANDHealth.

“Following the pandemic we have seen a retraction in innovation teams and investment in Australia, especially from global health industry players. Hopefully, this recognition puts Australian innovation squarely back on the radar. We are hoping to grow our partner network substantially over the coming years, enabling us to provide greater support, and accelerate the transition of our portfolio companies into international markets.”